BOTULINUM TOXIN FOR TREATMENT OF MIGRAINE HEADACHES – A STUDY FROM TERTIARY EYE CARE CENTRE

Author:

Haimanti Choudhury1,Hirendra K Choudhury2

Affiliation:

1. MS, FSSN, Choudhury Eye Hospital & Research Centre, Shyamaprasad Road Shillongpatty ,Silchar,Assam,India

2. MS, Choudhury Eye Hospital & Research Centre, Shyamaprasad Road (Shillongpatty),Silchar,Assam,India

Abstract

Background - Migraine is one of the common causes of recurrent headaches. Botulinum toxin type A (Botox®) is a neurotoxin produced by Clostridium botulinum that paralyzes nerves. The purpose of this study was to evaluate the efficacy of pericranial Botox® administration in migraine headache in patients attending a tertiary eye care centre. Method - A prospective,non-randomized study consisting of 54 patients was performed.Subjects were candidates who either sought Botox® treatment for hyperfunctional facial lines with concomitant headache or candidates for Botox® treatment specifically for headaches. Headaches were classified based on International Headache Society criteria. Botox® was injected into the glabellar,temporal,frontal,and/or suboccipital regions of the head and neck.Patients were treated every three months,with a maximum of three sessions.Botox dosage ranged from 75 - 155 Units per patient.Main outcome measures were relief from migraine headache symptoms, reduction of headache severity and duration of symptom free period. Results - Age ranged from 18 to 65 (mean 34.6±6.5) years. Among 54 subjects treated prophylactically,complete response (symptom elimination) was noted in 31 (57.40%) with a mean {Standard deviation – (SD)} response duration of 4.3 (2.4) months; 16 (29.62%) reported partial response (≥50% reduction in headache frequency or severity) with a mean (SD) response duration of 2.5 (1.7) months. 7 (12.96%) reported no response. No systemic adverse effects were reported.Conclusion - Botox® is found to be a safe and effective therapy for prophylactic treatment of migraine.

Publisher

World Wide Journals

Subject

Visual Arts and Performing Arts,Communication,Energy Engineering and Power Technology,Renewable Energy, Sustainability and the Environment,Electrical and Electronic Engineering,Computer Science Applications,Mechanical Engineering,Transportation,Cardiology and Cardiovascular Medicine,Molecular Biology,Molecular Biology,Structural Biology,Catalysis,General Engineering,Physical and Theoretical Chemistry,Process Chemistry and Technology,Catalysis,Process Chemistry and Technology,Biochemistry,Bioengineering,Catalysis,Cell Biology,Genetics,Molecular Biology,General Medicine

Reference21 articles.

1. Alberto Jaime Kalach-Mussali and Daniel Mondlak Algazi ; Botulinum Toxin E book. Nikolay Serdev; BotulinumToxin for the Treatment of Chronic Migraines. IntechOpen; 2018: 103-21

2. World Health Organization. The Global Burden of Disease. Geneva: World Health Organization; 2004. Available from: http://www.who.int/healthinfo/global_burden_disease/ GBD_report_2004update_full.pdf [Accessed: 2018-05-10]

3. Ray BK, Paul N, Hazra A, Das S, Ghosal MK, Misra AK et al.; Prevalence, burden, and risk factors of migraine: A community-based study from Eastern India. Neurol India 2017;65:1280-8

4. AteŞ Y; Botulinum toxin for the treatment of headaches: a review of current practices and evidence-based data. Agri 2006; 18(3):5-11.

5. Claus M Escher, Lejla Paracka, Dirk Dressler and Katja Kollewe; Botulinum toxin in the management of chronic migraine: clinical evidence and

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3